Table 3

Retrospective studies on platinum-based chemotherapy in patients with advanced homologous recombination-deficient PDAC

Mutations	Design	Therapy line	Therapy	Number of pts.	mPFS	mOS	Efficacy	Reference
Group 1: BRCA1/2, PALB2 (n=38) Group 2: ATM/ATR/ATRX (n=22) Group 3: BAP1, BARD1, BRIP1, CHEK1/2, RAD50/51/51B, FANCA/C/D2/E/F/G/L (n=12)	Retrospective	Various	Platinum-containing any therapy line Platinum-naïve	Total: 443 HRD: 72 HRP: 371	First-line: HRD+platinum (n=53): 13.7 m HRP+platinum (n=268): 8.2 m Second-line: HRD+platinum (n=28): 8.6 m HRP+platinum (n=103): 4.1 m	HRD+platinum (n=53): 2.37 y HRD-platinum (n=19): 0.76 y HRP+platinum (n=258): 1.45 y HRP-platinum (n=113): 1.13 y	HRD+platinum: p=0.001	83
BRCA1 BRCA2	Retrospective	First-line	Platinum-containing any therapy line Platinum-naïve	Total: 43	n.a.	HRD+platinum (n=22): 22 m HRD-platinum (n=21): 9 m	p=0.0389	84
BRCA1 (n=7) BRCA2 (n=5) PALB2 (n=3) MSH2 (n=1) FANCF (n=1)	Retrospective	First-line	FOLFIRINOX	Total: 36 HRD: 12	n.a.	HRD: 14 m HRP: 5 m	HRD vs HRP: p=0.08	126
BRCA2 (n=10) ATM (n=8) BRCA1 (n=2) CHEK2 (n=2) ATR (n=1) PALB2 (n=1)	Retrospective	Various	Platinum-containing any therapy line	Total: 28 HRD: 13	HRD+platinum: 20.8 m HRP+platinum : 1.7 m	n.a.	p=0.049	127
gBRCA2 (n=3) BRCA2 (n=2) BRCA1 (n=1) POLE (n gRAD51C (n=1) gMUTYH (n=1)	Retrospective	First-line	FOLFIRINOX	Total: 40	HRD+platinum: 18.5 m HRP+platinum: 6.9 m	11.5 m	mPFS: p=0.003	128
BRCA1 (n=5) BRCA2 (n=17) PALB2 (n=4)	Retrospective	Various	Platinum-containing any therapy line	Total: 78 HRD: 26 HRP: 52	HRD+platinum: 10.1 m HRP+platinum: 6.9 m	HRD+platinum: 24.6 m HRP+platinum: 18.8 m	mPFS: p=0.0068 mOS: p=0.0467	129

FOLFIRINOX, folinic acid, fluouracil, irinotecan, oxaliplatin; HRD, homologous recombination-deficient; HRP, homologous recombination-proficient; m, month; mOS, median overall survival; mPFS, median progression-free survival; n.a., not applicable; pts., patients; y, year.